Business Context and Reporting Period
Company: Regencell Bioscience Holdings Ltd (RGC)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: An early-stage Cayman Islands holding company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for neurocognitive disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). The company has no approved products and has not generated revenue from product sales. Operations are conducted primarily through Hong Kong subsidiaries.
Key Financial Metrics
| Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,584,213) | $(4,363,221) |
| Operating Expenses | $(3,769,985) | $(4,736,726) |
| Other Income, Net | $185,772 | $373,505 |
| Cash and Cash Equivalents (End of Period) | $2,419,115 | $2,961,235 |
| Short-term Investments | $2,477,900 | $5,000,000 |
| Total Assets | $5,755,582 | $8,438,211 |
| Accumulated Deficit | $(25,201,116) | $(21,616,903) |
| Net Cash Used in Operating Activities | $(3,113,576) | $(4,001,687) |
Note: All share data reflects a 38-for-1 forward stock split effected on June 13, 2025. As of June 30, 2025, there were 494,488,908 ordinary shares outstanding.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $779,000 (18%) compared to the prior year, primarily driven by a reduction in total operating expenses.
- Operating Expenses: Total operating expenses declined by $966,741 (20%).
- General and Administrative (G&A): Decreased by $731,384 (21%) due to lower share-based compensation, depreciation on fully depreciated assets, and reduced payroll/bonuses.
- Research and Development (R&D): Decreased by $117,944 (11%) mainly due to lower rental expenses for office and staff quarters.
- Selling and Marketing: Decreased significantly by $117,413 (94%) due to reduced marketing initiatives.
- Other Income: Decreased by $187,733 (50%) primarily due to lower interest income from short-term investments and bank deposits.
- Liquidity Position: Cash and cash equivalents decreased by approximately $542,000. Short-term investments decreased by approximately $2.52 million as maturities were realized and partially reinvested.
Guidance, Outlook, Risks, and Contingencies
Going Concern Uncertainty
The independent auditor has included an explanatory paragraph regarding "substantial doubt" about the company's ability to continue as a going concern. This is due to recurring losses, negative cash flows from operations, and an accumulated deficit of $25.2 million. The company's ability to continue is contingent upon raising additional capital.
Outlook and Strategy
The company expects to continue incurring losses for the foreseeable future as it advances efficacy trials for its standardized TCM formula. Management is pursuing cost-saving initiatives and seeking additional financing in public and private markets. The company plans to commercialize its TCM formula in Hong Kong first, pending regulatory approval from the Hong Kong Chinese Medicines Board.
Material Risks
- Regulatory Approval: No products are currently approved. Success depends on obtaining regulatory approval in Hong Kong and other jurisdictions, which is uncertain and costly.
- Capital Needs: Limited sources of working capital; failure to secure financing could force curtailment of operations.
- Internal Controls: The company identified three material weaknesses in internal control over financial reporting, including a lack of skilled staff with U.S. GAAP knowledge, lack of an internal audit function, and lack of segregation of duties.
- Legal Proceedings: The company is cooperating with an investigation by the U.S. Department of Justice (DOJ) regarding recent volatility in its share price. The outcome is uncertain and could result in fines or penalties.
- Key Personnel: The business is wholly dependent on the strategic partnership with Mr. Sik-Kee Au (the TCM Practitioner) and the CEO, Mr. Yat-Gai Au.
- PFIC Status: The company believes it was a Passive Foreign Investment Company (PFIC) for the taxable year ended June 30, 2025, which may have adverse tax consequences for U.S. holders.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of current cash ($2.4M) and short-term investments ($2.5M) against the burn rate of ~$3.1M annually to assess immediate liquidity risk.
- DOJ Investigation: Monitor updates regarding the Department of Justice investigation into share price volatility and potential financial penalties.
- Internal Control Remediation: Review progress on remediation plans for the three identified material weaknesses in financial reporting controls.
- Regulatory Milestones: Track the status of the second efficacy trial and the timeline for applying for registration with the Hong Kong Chinese Medicines Board.
- Shareholder Concentration: Note that the CEO and his spouse beneficially own approximately 88.6% of outstanding shares, exerting significant control.
- PFIC Implications: Consult tax advisors regarding the tax implications of the company's PFIC status for U.S. investors.